CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 192 enrolled
Drug / intervention
olmesartan medoxomil +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00403481
NCT00403481Phase 4Completed

A Prospective, Open Label, Single Arm Study to Evaluate the Safety and Efficacy of an Olmesartan Medoxomil Based Treatment Regimen in Type II Diabetic Patients With Hypertension

Daiichi Sankyo·interventional·Posted Nov 23, 2006·Updated Nov 3, 2016

In Brief

A Phase 4 clinical trial evaluating olmesartan medoxomil and Olmesartan medoxomil plus Hydrochlorothiazide for Hypertension. Completed, enrolled 192 participants across 27 sites.

Detailed Summary

This study will examine the ability of olmesartan medoxomil to lower the blood pressure of patients with Type II diabetes and high blood pressure. The medication being tested has been approved by the FDA for the treatment of high blood pressure.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 23, 2006
Enrollment StartNov 1, 2006
Primary CompletionNov 1, 2007
Study CompletionDec 1, 2007
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 19.6 years ago

Interventions

olmesartan medoxomildrug

Olmesartan medoxomil tablets, once daily

Olmesartan medoxomil plus Hydrochlorothiazidedrug

Olmesartan medoxomil and hydrochlorothiazide combination tablets, once daily, if necessary